Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Now just about on the radar. Why sell?
Matt Sassone, CEO of LiDCO, said: "This ESICEM webinar has highlighted two key measurements to assist in the treatment of COVID-19 patients, the end expiratory occlusion test (EEOT) and tidal volume challenge (TVC), which LiDCO's technology already has in-built. This demonstrates once again the core benefits of our technology in the critical care environment and our technology leadership in the advanced hemodynamic monitoring market. I am proud of how our team met the challenge of a substantial surge in orders in Q1, thereby doing our part to help hospitals and patients affected by Covid-19."
This announcement contains inside information
for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR)
LiDCO Group Plc
("LiDCO" or the "Company")
Hemodynamic management in COVID-19 patients and Q1 sales update
LiDCO (AIM: LID), a leading supplier of hemodynamic monitoring solutions, welcomes the recent educational webinar from the European Society of Intensive Care Medicine ('ESICEM') regarding hemodynamic management in COVID-19 patients. The panel consisted of four international experts who discussed current World Health Organisation COVID-19 treatment guidelines and explored the patient benefits of using advanced hemodynamic monitoring in such treatment.
During the discussions, Senior Consultant Antonio Messina at Humanitas Hospital, Italy discussed the frontline strategies for treating COVID-19 patients and the importance of managing these ventilated patients' physiology with functional hemodynamic tests. During Dr Messina's speech he called out the importance of using a combination of a ventilator and a hemodynamic monitor to perform an end expiratory occlusion test ('EEOT') to assess the patient's fluid status.
This point was reinforced by Professor Jacques Duranteau, Head of Anaesthesia and Critical Care at Bicetre hospital, Paris, who referenced the need to employ a conservative fluid strategy and discussed the use of another ventilator-associated method, the tidal volume challenge ('TVC'), as a means to assess a patient's fluid status to prevent giving COVID-19 patients any excess fluid.
To perform these tests requires a precise measurement of the patient's advanced hemodynamic parameters. The LiDCO monitor is able to meet this need to measure these small changes over a short period of time and is the only monitor on the market to have both the EEOT and TVC as in-built guided clinical protocols.
As previously announced in LiDCO's Full-Year Results release in April 2020, the Company has seen a strong lift in demand for its hemodynamic monitoring systems due to COVID-19. Over 200 monitors have been sold, predominately in the UK, in the first three months of the financial year compared with 219 sold in the whole of previous financial year. LiDCO has been able to supply the monitors to ICU units around the world where patients with the most acute symptoms of COVID-19 are being treated.
LiDCO sales in Q1 of this year (three months ended 30 April 2020) were £4.4m up 179% on the corresponding period last year. As expected, Q1 sales have therefore already significantly exceeded the total sales of £3.5m the Company achieved in H1 last year (6 months to 31 July 2019).
To listen to the ESICEM webinar click here: https://bit.ly/2VDerOI
To find out more information about EEOT and TVC click here: http://www.lidco.com/what-are-preload-responsive-ventilator-tests/
Matt Sassone, CEO of LiDCO, said: "This ESICEM webinar has highlighted two key measurement
This is a good steady growing business providing good kit to health services around the world - don't treat it the same pump and dump way other Covid related stocks have been
I just sliced some, nice. Letting all the rest ride now until t/o or hasn’t anyone else joined the dots yet. That’s the whole point of the expert endorsements. LID has the ONLY machine that does both. Build a machine or buy LID. Imo.
If it dips I may buy the ones I sold but only so much cash and the sweet shop is full!
Trek
HUGE RISE COMING
Covid19 play
10.8p paid, nice
There's 6 MMs according to Level 2.
Great RNS released this morning with revenue up +179% in Q1 and already £1m higher than the first 6 months last year. Also great news to see independent experts explaining the benefits of the LIDCO machines in treating COVID-19 patients which is why sales are so strong now. Webinar should be very interesting
....ahead of the webinar.
We are hosting a webinar with LiDCO on Tuesday which may be of interest. See: https://www.sharesoc.org/events/sharesoc-webinar-with-lidco-lid-5-may-2020/
It takes time, the finals were good they looked back but the guidance was outstanding. I am very impressed with this BoD and how they engage with there shareholders. If anyone hasn’t looked yet check out the last two ppt on the homepage. An excellent presentation and honest about how they included concerns that not all health authorities had had budgets set yet so there may be some order lag but that’s against exceptional guidance. Don’t always expect the herd to arrive with stocks, DCTA is another classic example, but eventually value will out.
LID has an impressive list of institutional holders. They’d have dug into the numbers and may well add thing is though there just isn’t the shares in float. The only way to get more here imo is to buy the lot and someone probably will.
All imo
Trek
This Q1 should be fantastic. I cannot understand why the traders havent descended on this stock and hoovered. It will have become much better known in UK and abroad and I see no reason why this pandemic should not be the making of LID. All IMHO and please DYOR. Keep safe everyone.
anticipate more sales and income, long term buy, pretty secure, ticks all the defensive boxes with good growth potential. Share price pressure probably Investment trust flogging off shares they haven’t taken a caneing on, short termism, as they say the market is very efficient at separating the impatient from their money. Hold on for long term gain or a possible bid in the near future.
RNS TR1
So to Jan 2020...
As at 31 January 2020, global contracted base of 286 HUP monitors (FY19: 164), generating total annualised contracted license revenues of £2.2m (FY19: £1.4m) an increase of 57%
From 1st Feb to 20 April....(post ye)....
Significant increased demand as a result of COVID-19 with 195 monitors sold to date, predominantly to the UK market, compared with 219 monitors sold in the whole of FY20
· Board expects that sales in the three months ending 30 April 2020 will significantly exceed total sales of £3.5m achieved in H1 FY20
So mostly UK hooked up. Assume a run-rate for simple numbers another 286 before next trading statement... or with same costs another 2.2m of annual contracted revenues, not to mention sales well in excess of £3.5m + other SaaS services.
I wouldn’t be surprised to see an early trading statement as the runrate change will be significantly different to the current guidance so as to warrant another market update!
What else is noteworthy is mostly UK sales and yet there were budgetary reservations in the slide pack as some hospitals around the world I guess had not set them (budgets) yet. Well it certainly seems UK is ok. US should be ok and likewise China.
Trying to be objective there could be a tail off year end, but then we get recurring revenues. There is so much to come in H1 imo just sit back and let the numbers do the talking. Apart from the usual trading blips I can’t think of much downside from here and could understand longer term traders parking money until Aug/Sep coz there should be blockbuster interim results or a takeover. All imo but i’m leaving my money in based on the evidence in front of me!
Trek
Delayed ............BUYS! 250K and 150K certainly not to be sniffed at!
Just trader's moving out mind I sold at 8.07 yesterday and will buy again as price settles
As always with AIM, ADHD, only way to look at it is to take a long term view providing you believe in the company. Doing everything right and with a potential windfall leading to prolonged royalties for the life of the equipment... One that will get you rich slowly.
unloading! They'll be sorry, I hope.
Makes my earlier buy look a little rash.
The good news is I can wait and the even better news is that I think the company will (and, actually, is) deliver (delivering).
To see 0 gains off the back of that is ridiculous.
I've read the strategic doc. No increase in requirement in the states as of yet is a direct quote.
Kiwi, they have formalised dates for q1 trading update? Or do you mean Q2?
Was this not it?
Further news on its way, Q1 trading update. Annual report/Accounts and AGM. All in the next couple of weeks, not to mention further updates on distribution into new countries.